Kolexia
Favier Laure Oncologie médicale
Favier Laure
Oncologie médicale
Centre Georges-François Leclerc
Dijon, France
114 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de l'ovaire Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Carcinome épithélial de l'ovaire Carcinomes Récidive tumorale locale Tumeurs de l'endomètre Tumeurs du sein

Collaborateurs

Voir plus
Coudert Bruno
Coudert Bruno
Centre Georges-François Leclerc, Dijon, France
Lagrange Aurelie
Lagrange Aurelie
Centre Georges-François Leclerc, Dijon, France
Arnould Laurent
Arnould Laurent
Centre Georges-François Leclerc, Dijon, France
Ghiringhelli Francois
Ghiringhelli Francois
Centre Georges-François Leclerc, Dijon, France

Industries

Voir plus
AstraZeneca
12 collaboration(s)
Dernière en 2023
Amgen
7 collaboration(s)
Dernière en 2023
Pfizer
6 collaboration(s)
Dernière en 2023
Janssen
5 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK): A Phase II Randomized, Open-Labelled, Multicenter Study of Safety & Efficacy of Combination Brigatinib and Carboplatin-Pemetrexed Therapy or Brigatinib Monotherapy as First-Line Treatment in Advanced ALK-Positive Non-Small Cell Lung Cancer
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   06 mars 2024
DOMENICA: Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting
Essai Clinique (GSK)   28 février 2024
AcSé: Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations
Essai Clinique (Unicancer)   06 décembre 2023
TEDOVA: Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
Essai Clinique (Merck & Co.)   04 décembre 2023
PembroSCCOHT: Multicentric Non-randomized Phase II of Pembrolizumab in Combination With Etoposide-cisplatin-based Chemotherapy in First-line Small Cell Ovarian Carcinoma of Hypercalcemic Type
Essai Clinique (Merck & Co.)   17 novembre 2023
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer: A Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating Efficacy and Safety of Inupadenant in Combination With Carboplatin and Pemetrexed in Adults With Nonsquamous Non-small Cell Lung Cancer Who Have Progressed on Immunotherapy
Essai Clinique (iTeos Belgium SA)   20 septembre 2023
Advancing precision oncology through systematic germline and tumor genetic analysis: The oncogenetic point of view on findings from a prospective multicenter clinical trial of 666 patients.
Cancer medicine   11 septembre 2023
CHIVA: Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023
Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes.
Molecular cancer   29 juillet 2023
UCPVax: Anticancer Therapeutic Vaccination Using Telomerase-derives Universal Cancer Peptides in Metastatic Non Small Cell Lung Cancer : A Phase I/II Study
Essai Clinique (Invectys)   13 juillet 2023